Macrophage Biomarkers CD68 and CD163 Correlate with CRC Patient Survival (Poster No. 2530 at #AACR2022)

Key Takeaways

  • CRC patient survival correlates with the presence or absence of macrophage biomarkers CD68, CD163, and a lack of PD-L1.
  • Lower levels of ‘M1/anti-tumor’ CD68+ or CD68+CD163 cells correlate with increased survival. Higher levels of ‘M2/pro-tumor’ CD163+ cells showed minimal correlation to survival.
  • Based on these observations, additional biomarkers are needed to better characterize macrophage phenotypes and understand their role in the tumor microenvironment.